FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer By Ogkologos - September 19, 2025 649 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Cohort 2 of SunRISe-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Study Links Mental Health Treatment to Improved Cancer Survival July 10, 2020 FDA Approves Nivolumab in Combination with Chemotherapy and Nivolumab in Combination... June 8, 2022 NHS England change of chief executive – what does it mean... August 19, 2021 Nivolumab Plus AVD Prolongs PFS in Adolescents and Adults with Advanced-Stage... October 30, 2024 Load more HOT NEWS Improving cancer care for the LGBTQ+ community Imetelstat Shows Durable Transfusion Independence and Disease-Modifying Activity in Heavily Transfused... How can we improve LGBTQ+ cancer care? – That Cancer Conversation... Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with...
